Head-to-head evidence
BI 1569912 vs Onfasprodil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
BI 1569912
Developed by Boehringer Ingelheim
NCT06280235 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 243 participants, using the clinical MADRS depression score as its primary endpoint. However, the prespecified primary dose-response analysis was not statistically significant, so the trial provides well-controlled but inconclusive evidence of benefit.
Onfasprodil
Developed by Novartis
NCT03756129 · Phase 2 · completed
Participants were randomized and blinded to MIJ821, placebo, or ketamine, but the 70-person study was small and spread across six treatment groups. The clinical primary endpoint was met at 24 hours for both pooled MIJ821 dose groups versus placebo, with statistically significant MADRS score differences, but the limited sample size supports moderate rather than strong evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BI 1569912's landscape · Onfasprodil's landscape